Home / Business and Economy / Attovia Therapeutics Files for US IPO
Attovia Therapeutics Files for US IPO
15 Jul
Summary
- Attovia Therapeutics filed for an initial public offering in the United States.
- The company develops biotherapeutics for immune-mediated diseases.
- Attovia plans to list on the Nasdaq Global Market under the symbol ATTO.
Biopharmaceutical company Attovia Therapeutics has officially filed for an initial public offering in the United States. This move aligns with a recent uptick in biotech IPOs, driven by improving investor confidence and a willingness to return to public markets.
Attovia Therapeutics specializes in the development of innovative biotherapeutics targeting immune-mediated diseases. Their therapeutic approach is powered by the company's proprietary ATTOBODY platform.
The company intends to trade on the Nasdaq Global Market, with the stock symbol "ATTO." This offering is being managed by a syndicate of underwriters, including prominent firms such as Morgan Stanley, Leerink Partners, Citigroup, and RBC Capital Markets.
